Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New lengths of Cordis' biliary stent

This article was originally published in Clinica

Executive Summary

Cordis has received 510(k) marketing clearance from the US FDA for new lengths of its S.M.A.R.T. Nitinol transhepatic biliary stent. The approval covers lengths of 120 and 150mm. These stents are designed for the palliative treatment of malignant strictures in the biliary tree that can restrict the flow of digestive fluids and compromise digestion. Cordis, a subsidiary of Johnson & Johnson, said that the S.M.A.R.T. devices may decrease the need for additional stents to cover the full narrowing of the bile duct.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046508

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel